Skip to main content
[Preprint]. 2021 Jun 11:rs.3.rs-600795. [Version 1] doi: 10.21203/rs.3.rs-600795/v1

Table 1.

Baseline Characteristics of Symptomatic Adult Patients Hospitalized with COVID-19

History of Cancer
Characteristic No (N = 7330) Yes (N = 892) p
Age (years) 60.4 (17.4) 70.6 (14.1) < 0.001
Female Sex 3231 (44.1) 421 (47.2) 0.077
BMI (kg/m2) 30.6 (8.2) 28.5 (7.7) < 0.001
Race White 4522 (61.7) 598 (67.0) 0.009
Black 1736 (23.7) 194 (21.8)
Asian/Pacific Islander 469 (6.4) 46 (5.2)
Other 603 (8.2) 54 (6.1)
Payment Source Uninsured 521 (7.1) 22 (2.5) < 0.001
Private 3946 (54.0) 459 (51.6)
Medicare 1267 (17.4) 274 (30.7)
Medicaid 1310 (17.9) 124 (13.9)
Other 259 (3.6) 11 (1.2)
Atrial Fibrillation/Flutter 626 (8.5) 131 (14.7) < 0.001
Diabetes Mellitus 2722 (37.1) 328 (36.8) 0.832
Pulmonary Disease 2522 (34.4) 380 (42.6) < 0.001
Chronic Kidney Disease 928 (12.7) 146 (16.4) 0.002
Hypertension 4287 (58.5) 616 (69.1) < 0.001
Smoking History 461 (6.3) 61 (6.8) 0.53
Pulmonary Disease 1305 (17.8) 203 (22.8) <0.001
Admission Symptoms
Fever/Chills 4823 (65.8) 550 (61.7) 0.014
Cough 4867 (66.4) 534 (59.9) < 0.001
Shortness of Breath 4552 (62.1) 513 (57.5) 0.008
Fatigue 1845 (25.2) 232 (26.0) 0.59
Headache 722 (9.9) 49 (5.49) < 0.001
Myalgia 1580 (21.6) 188 (21.1) 0.74
Sore Throat 506 (6.9) 53 (5.94) 0.28
Nasal Congestion 375 (5.1) 53 (5.94) 0.30
Nausea/Vomiting/Diarrhea 2066 (28.2) 254 (28.5) 0.86
Loss of Smell/Taste 303 (4.1) 44 (4.9) 0.26
Confusion or AMS 770 (10.5) 145 (16.3) < 0.001
COVID-19 Therapies
Corticosteroid 1547 (21.8) 203 (24.7) 0.056
Immunoglobulin 53 (0.7) 12 (1.4) 0.05
Convalescent serum 195 (2.7) 27 (3.1) 0.54
Ritonavir/Lopinavir 76 (1.1) 7 (0.9) 0.60
Remdesivir 565 (7.8) 105 (11.9) < 0.001
Tocilizumab 523 (7.2) 62 (7.0) 0.82
Chemotherapy/biologics 14 (0.19) 124 (14.0) < 0.001
History of CVD 1544 (21.1) 261 (29.3) < 0.001

Values are depicted as mean (standard deviation) or percentage (N) when appropriate.

BMI, Body Mass Index; CVD, Cardiovascular Disease; AMS, Altered Mental Status